Mounjaro and Ozempic are different drugs from different companies. Mounjaro is tirzepatide, made by Eli Lilly. Ozempic is semaglutide, made by Novo Nordisk. Both are FDA-approved for type 2 diabetes, not for weight loss. Here is the full molecule comparison.
Most people searching "Mounjaro vs Ozempic" are really asking which is better for weight loss. Neither brand carries a weight-loss indication. Their weight-management siblings do, under different names.
This guide compares the brands: what is in each pen, what each label permits, what the one head-to-head trial found, and what to do if neither is available.
Two Molecules, Two Makers, Two Diabetes Labels
The brand names hide the more important distinction, at the molecule level. Tirzepatide activates two receptors, GIP and GLP-1. Semaglutide activates one, GLP-1. That structural difference drives everything else here.
Each molecule is sold under more than one brand name, and the brand determines the approved use, not the ingredient. This is why "Ozempic vs Mounjaro" and "tirzepatide vs semaglutide brands" return tangled results: four brand names, two molecules.
For molecule-level detail, see What Is Tirzepatide and What Is Semaglutide.
Mounjaro vs Ozempic at a Glance
| Mounjaro | Ozempic | |
|---|---|---|
| Active molecule | Tirzepatide | Semaglutide |
| Drug class | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| Maker | Eli Lilly | Novo Nordisk |
| FDA-approved use | Glycemic control in type 2 diabetes, adults and patients aged 10 and older | Glycemic control in type 2 diabetes in adults, plus cardiovascular and kidney risk reduction in defined groups |
| Weight-management sibling | Zepbound (same molecule) | Wegovy (same molecule) |
| Label dose range | 2.5 mg to 15 mg weekly, in 2.5 mg steps at least 4 weeks apart | 0.25 mg to 2 mg weekly, stepped at least 4 weeks apart |
| Delivery | Weekly subcutaneous injection, single-dose pen and KwikPen | Weekly subcutaneous injection, multi-dose pen |
| Oral version of the molecule | None approved | Yes, as oral tablets under the Rybelsus, Ozempic and Wegovy tablet labels |
| Boxed warning | Thyroid C-cell tumors in rodents | Thyroid C-cell tumors in rodents |
Neither Brand Is Approved for Weight Loss
This is the most useful correction for anyone comparing these two names. The Mounjaro prescribing information lists one indication: glycemic control in type 2 diabetes. The Ozempic prescribing information covers glycemic control plus risk reduction for major cardiovascular events and kidney decline, each in specified type 2 diabetes populations.
Weight loss appears in neither list. Both labels position the drug as an adjunct to diet and exercise for blood sugar, with weight change reported as a trial finding, not an approved use.
The weight-management approvals sit with the sibling brands. Zepbound is tirzepatide, approved for chronic weight management (2023) and for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). Wegovy is semaglutide, approved for chronic weight management, with cardiovascular risk reduction added after the SELECT trial and a later approval for noncirrhotic MASH with moderate to advanced liver fibrosis.
So a "Mounjaro vs Wegovy" or "Zepbound vs Ozempic" search compares a diabetes brand against a weight brand. Like for like, it is Zepbound against Wegovy for weight, Mounjaro against Ozempic for diabetes. More on naming in Is Mounjaro Tirzepatide, Is Ozempic Semaglutide, and Is Zepbound the Same as Tirzepatide.
SURPASS-2: The One Head-to-Head Trial
Most brand comparisons set results side by side from separate studies, which is not a fair test. One trial did randomize participants directly between these two molecules.
SURPASS-2 was an open-label, 40-week phase 3 trial assigning 1,879 adults with type 2 diabetes to tirzepatide 5, 10 or 15 mg, or semaglutide 1 mg, all once weekly on top of metformin.
Mean baseline HbA1c was 8.28 percent. Estimated mean HbA1c reductions were 2.01, 2.24 and 2.30 percentage points for tirzepatide 5, 10 and 15 mg, against 1.86 percentage points for semaglutide 1 mg. Tirzepatide was noninferior and superior to semaglutide on the primary endpoint at every dose.
Weight reductions were also greater with tirzepatide, with least-squares mean estimated treatment differences of 1.9 kg, 3.6 kg and 5.5 kg. Gastrointestinal events were most common in both groups, primarily mild to moderate.
What SURPASS-2 Does Not Settle
The trial is real evidence, and narrower than headlines suggest. Three limits matter.
- The comparison dose was 1 mg. That was the approved Ozempic dose at the time. Ozempic now goes to 2 mg and Wegovy titrates to 2.4 mg. SURPASS-2 tested neither.
- The population had type 2 diabetes. Every participant was on background metformin. The results do not transfer directly to people without diabetes seeking weight management.
- It was open-label. Participants and investigators knew which drug was given, a recognized limitation for subjective outcomes such as tolerability.
Serious adverse events were reported in 5 to 7 percent of tirzepatide participants and 3 percent of semaglutide participants. Tirzepatide outperformed semaglutide 1 mg on the measured endpoints in this population, but a "best drug" verdict does not follow from one trial.
Brand names aside, the real decision is which molecule a licensed provider thinks fits your history. Compare tirzepatide and semaglutide side by side before you start.
Compare tirzepatide and semaglutideSide Effects: The Labels Warn About the Same Things
People often assume one brand is gentler. The labels are more alike than different. Both carry a boxed warning for thyroid C-cell tumors seen in rodents, and both are contraindicated with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2.
Common adverse effects for both are gastrointestinal: nausea, vomiting, diarrhea and constipation, usually worst while the dose is stepped up. Serious but less common risks on both labels include pancreatitis and gallbladder disease. Neither molecule is for use in pregnancy.
Managing the gastrointestinal phase is covered in GLP-1 side effects and nausea management and Tirzepatide Side Effects.
The Pens Differ, and Only One Molecule Has a Pill
Mounjaro comes as a single-dose pen and a KwikPen in six strengths from 2.5 mg to 15 mg. Ozempic uses a multi-dose pen delivering several weekly doses from one device, which is why its pens are labeled by total milligrams.
There is a genuine asymmetry on the oral side. Semaglutide exists as a tablet; tirzepatide does not. Oral semaglutide is sold as Rybelsus at 3, 7 and 14 mg, and the same labeling now covers Ozempic tablets at 1.5, 4 and 9 mg, both for type 2 diabetes. The Wegovy label also covers tablets, for weight management and cardiovascular risk reduction.
No FDA-approved tirzepatide pill exists. Foundayo, the oral GLP-1 pill approved in 2026, contains orforglipron, a different molecule entirely. See The Semaglutide Pill and Tirzepatide Pills and Oral Tirzepatide, and Mounjaro and Zepbound Pens vs Compounded Vials for the device comparison.
If You Cannot Access Either Brand
Cost and coverage decide this for many people: a diabetes label often means no coverage when the reason for taking it is weight. Brand pricing shifts often, so check current figures in Tirzepatide Cost and Semaglutide Cost.
Compounded preparations of the same molecules are one route people ask about. Compounded tirzepatide and compounded semaglutide are not FDA-approved. Licensed US compounding pharmacies prepare them against a prescription for an individual patient, and they need not match a brand's concentration or presentation.
Telos Rx is an online-first, asynchronous telehealth service. You complete a written intake and a licensed provider reviews it in writing, without a scheduled appointment. Everything is subject to medical approval by a licensed provider, and approval is not guaranteed. As of publication, compounded tirzepatide is listed as low as $139/mo and compounded semaglutide as low as $99/mo, with flat pricing that does not rise with dose, free 48-hour shipping if approved, FSA and HSA accepted, and cancel anytime.
Keep Reading
- Tirzepatide vs Semaglutide: Compounded Options Explained
- Tirzepatide Dosage: The Titration Schedule Explained
- Semaglutide Dosage: The Titration Schedule Explained
- How to Get Tirzepatide Online Safely
Frequently Asked Questions
Which is better, Mounjaro or Ozempic?
In SURPASS-2, the only trial to compare them head to head, tirzepatide at all three doses produced greater HbA1c and weight reductions than semaglutide 1 mg over 40 weeks in adults with type 2 diabetes. That is one trial, at one semaglutide dose, in one population. Which drug suits you is a decision for a licensed provider.
Is Mounjaro the same as Ozempic?
No. They contain different active molecules from different manufacturers. Mounjaro is tirzepatide from Eli Lilly and activates both GIP and GLP-1 receptors. Ozempic is semaglutide from Novo Nordisk and activates GLP-1 receptors only. They are not interchangeable, and the doses do not convert between them.
Can I get Mounjaro or Ozempic for weight loss?
Neither brand carries an FDA-approved weight-loss indication. Both are approved for type 2 diabetes. The weight-management brands are Zepbound for tirzepatide and Wegovy for semaglutide. A prescriber decides what is appropriate, and coverage for a diabetes brand is often declined when the reason for taking it is weight.
Which has worse side effects, Mounjaro or Ozempic?
Their warnings are closely matched. Both carry a boxed warning about thyroid C-cell tumors in rodents and both list pancreatitis and gallbladder disease as serious risks. Gastrointestinal effects such as nausea and diarrhea are the most common for both and are usually worst during dose escalation. Individual tolerance varies.
Is there a Mounjaro pill or an Ozempic pill?
There is no FDA-approved tirzepatide pill, so no Mounjaro tablet exists. Semaglutide does come as a tablet, sold as Rybelsus and, under the same labeling, as Ozempic tablets, both for type 2 diabetes. Foundayo, approved in 2026, is an oral GLP-1 pill containing orforglipron, a different molecule entirely.
Are compounded tirzepatide and semaglutide the same as the brands?
They contain the same active molecules but they are not FDA-approved, and they are not required to match a brand's concentration or presentation. Licensed US compounding pharmacies prepare them against a prescription for an individual patient. Availability and formulation can vary, and provider oversight is required in every case.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Still weighing the two? Compare them on the tirzepatide vs semaglutide page, then complete the written intake: start an online visit. Every request is reviewed by a licensed provider, and approval is not guaranteed.